attana - sensor technologies

Attana in Swedish Life Sciences

Swedes are well known to be innovative and building successful global companies and international brands. In Swedish Life Sciences many of the Swedish companies representing the entire health care spectrum are compiled and presented and there among Attana.

The Life Science segment in Sweden is strong with cutting-edge technology, highly educated employees and companies representing the entire health care spectrum – from small start-up companies to universities and big industries, working in the entire range from biotech to medical technology, pharmaceuticals and health care services. In Swedish Life Sciences many of these companies are compiled and presented, there among Attana AB.

"Swedish Life Sciences is published in conventional and electronic form. As a beautifully produced hardback book, copies are distributed free of charge throughout the world, and are available at a number of important trade fairs and conferences related to the industry. Additional copies are available on request from Horn Publishing, which also publishes similar books on a range of business sectors and industries in a growing number of countries. When ordering additional copies of the books please explain why you want them and what you plan to do with them".

 See the full Attana presentation p. 87 in Swedish Life Sciences, published in October 2012.

Fast track to drugability - gain Time-to-Market

Success in clinical trials is dependent on correct information about the drug candidate and target interaction. Failure, on the other hand, is often due to a lack of relevant information in the selection process. By improved selection of drug candidates during the pre-clinical phase the success rate of clinical trials will increase. The Attana Cell 200 biosensor has the unique ability to provide biologically relevant information through measurement of molecular interactions directly in complex conditions such as sera or to human cells. By delivering biologically relevant information at an early stage in the drug discovery process, the Attana Cell 200 minimizes risks and costs and increases success rate during clinical trials.

Attana’s journey towards providing biological relevant data began with our first generation of real-time, label-free biosensor providing high quality data. It continued with our 2nd generation instrument with the capability to detect interactions in crude biological samples or sera. Today our 3rd generation instrument provides the unique ability to perform kinetic characterization of molecular interactions taking place on the cell surface. Our ambition to understand true interaction dynamics is our guiding star when designing new biosensors. Avoiding the efforts and adverse effects associated with labelling and target purification, Attana’s biosensors are designed for realtime, label-free measurements of molecular interactions under physiological conditions.

The way to obtain more biologically relevant data is to achieve a physiologically relevant condition inside the biosensor. Since drug candidates and targets alike do not exist in a purified environment, the results from experiments with purified reagents are not an accurate indicator of what actually happens in the human body. Another efficient way to improve the selection of drug candidate is to measure interactions directly as they happen on the cell surface. The 3rd generation instrument, Attana Cell 200, can perform real-time, label-free characterization of molecular interactions in either a biochemical or cellular environment (using immobilized cells), enabling the investigation of the dynamic properties and concentration and time dependent nature of binding, as well as the identification of off-target interactions. This allows researchers to compare the kinetic characteristics of a lead antibody in an idealized in vitro environment with its behaviour in the more biologically relevant context of crude samples or sera, at a cellular level. This gives a more accurate picture of whether the desired characteristics of a lead antibody will be maintained in the presence of lipids, proteins, and carbohydrates, as well as identifying potential conjugate and off-target effects, avidity, and internalization of receptors, helping to select the right antibody lead for further development.